Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radioresistance in rhabdomyosarcomas: Much more than a question of dose.
Camero S, Cassandri M, Pomella S, Milazzo L, Vulcano F, Porrazzo A, Barillari G, Marchese C, Codenotti S, Tomaciello M, Rota R, Fanzani A, Megiorni F, Marampon F. Camero S, et al. Among authors: marampon f. Front Oncol. 2022 Sep 29;12:1016894. doi: 10.3389/fonc.2022.1016894. eCollection 2022. Front Oncol. 2022. PMID: 36248991 Free PMC article. Review.
DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Megiorni F, Camero S, Ceccarelli S, McDowell HP, Mannarino O, Marampon F, Pizer B, Shukla R, Pizzuti A, Marchese C, Clerico A, Dominici C. Megiorni F, et al. Among authors: marampon f. Oncotarget. 2016 Nov 29;7(48):79342-79356. doi: 10.18632/oncotarget.12688. Oncotarget. 2016. PMID: 27764816 Free PMC article.
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
Megiorni F, Gravina GL, Camero S, Ceccarelli S, Del Fattore A, Desiderio V, Papaccio F, McDowell HP, Shukla R, Pizzuti A, Beirinckx F, Pujuguet P, Saniere L, der Aar EV, Maggio R, De Felice F, Marchese C, Dominici C, Tombolini V, Festuccia C, Marampon F. Megiorni F, et al. Among authors: marampon f. J Hematol Oncol. 2017 Oct 6;10(1):161. doi: 10.1186/s13045-017-0530-z. J Hematol Oncol. 2017. PMID: 28985758 Free PMC article.
Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines.
Giannattasio S, Megiorni F, Di Nisio V, Del Fattore A, Fontanella R, Camero S, Antinozzi C, Festuccia C, Gravina GL, Cecconi S, Dominici C, Di Luigi L, Ciccarelli C, De Cesaris P, Riccioli A, Zani BM, Lenzi A, Pestell RG, Filippini A, Crescioli C, Tombolini V, Marampon F. Giannattasio S, et al. Among authors: marampon f. J Endocrinol Invest. 2019 Feb;42(2):183-197. doi: 10.1007/s40618-018-0900-6. Epub 2018 May 22. J Endocrinol Invest. 2019. PMID: 29790086
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Camero S, Ceccarelli S, De Felice F, Marampon F, Mannarino O, Camicia L, Vescarelli E, Pontecorvi P, Pizer B, Shukla R, Schiavetti A, Mollace MG, Pizzuti A, Tombolini V, Marchese C, Megiorni F, Dominici C. Camero S, et al. Among authors: marampon f. J Cancer Res Clin Oncol. 2019 Jan;145(1):137-152. doi: 10.1007/s00432-018-2774-6. Epub 2018 Oct 24. J Cancer Res Clin Oncol. 2019. PMID: 30357520 Free PMC article.
Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
Marampon F, Leoni F, Mancini A, Pietrantoni I, Codenotti S, Ferella L, Megiorni F, Porro G, Galbiati E, Pozzi P, Mascagni P, Budillon A, Maggio R, Tombolini V, Fanzani A, Gravina GL, Festuccia C. Marampon F, et al. J Cancer Res Clin Oncol. 2019 Feb;145(2):393-409. doi: 10.1007/s00432-018-2800-8. Epub 2018 Nov 24. J Cancer Res Clin Oncol. 2019. PMID: 30474756
145 results